Dasatinib is a multikinase inhibitor targeting ABL and Src family kinases, which is approved for use in imatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) [15, 16]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.